-
Mashup Score: 1
Michelle Xia represents a rising generation of biotech companies in China challenging Western giants.
Source: www.wsj.comCategories: General Medicine NewsTweet
-
Mashup Score: 1More than the sum: How vascular endothelial growth factor inhibition unlocks the full potential of immune checkpoint blockade - 9 day(s) ago
The combination of antiangiogenic and immune checkpoint inhibitor (ICI) treatment is active in solid tumors, but the mechanism of response remains unclear. In this issue of Immunity, Benmebarek et al. show that anti-vascular endothelial growth factor enhances ICI by reprogramming regulatory T cells into a fragile state.
Source: www.cell.comCategories: General Medicine NewsTweet-
4/ @DanielShuMD and my commentary on this new paper: https://t.co/qVRdCKW2SM
-
-
Mashup Score: 34
VEGF blockade is known to enhance immune checkpoint blockade (ICB) efficacy, but its precise immunological mechanism remains undefined. Benmebarek et al. reveal that VEGF inhibition drives BAFF- and IL-12-dependent Treg reprogramming, promoting a fragile, Th1-like state that amplifies anti-tumor immunity in cholangiocarcinoma.
Source: www.cell.comCategories: General Medicine NewsTweet-
1/ Exciting work published in Immunity from @TimGreten et al. showing that anti-VEGF enhances the antitumor activity of PD-L1 + CTLA-4 blockade by inducing a fragile Treg phenotype via BAFF and IL-12 📄 https://t.co/ZcmyEKIZcY
-
-
Mashup Score: 1Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer - 18 day(s) ago
Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete…
Source: www.globenewswire.comCategories: General Medicine NewsTweet-
Wonderful to see that #tovecimig is active in #cholangiocarcinoma, hitting primary ORR endpoint (17 vs 5%)! Potentially a future standard option for patients… but toxicity/PFS/OS will be important to evaluate as well: https://t.co/71PdRBXllI
-
-
Mashup Score: 24Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial - 2 month(s) ago
Nature Medicine – In this phase 1 trial, patients with locally advanced or metastatic solid tumors were treated with the individualized mRNA neoantigen-specific immunotherapy (iNeST) autogene…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
Autogene cevumeran ± atezolizumab in advanced solid tumors: 🔗 https://t.co/fcnSabyFh5 1️⃣ Some vaccine monotherapy activity in advanced cancers (a CR in MMRd gastric) 2️⃣ But —who would leave an ICI-naïve MMRd patient off an ICI? 🤔 https://t.co/hEx5IIu5Lv
-
-
Mashup Score: 297Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade - 3 month(s) ago
Background Obesity is a risk factor for developing cancer but is also associated with improved outcomes after treatment with immune checkpoint inhibitors (ICIs), a phenomenon called the obesity paradox. To interrogate mechanisms of divergent immune responses in obese and non-obese patients, we examined the relationship among obesity status, clinical responses, and immune profiles from a diverse, pan-tumor cohort of patients treated with ICI-based therapy. Methods From June 2021 to March 2023, we prospectively collected serial peripheral blood samples from patients with advanced or metastatic solid tumors who received ICI as standard of care at Johns Hopkins. Patients were stratified by obesity status at treatment initiation, with obesity defined as body mass index (BMI)≥30 at treatment initiation and BMI≥18.5 and <30 considered non-obese; underweight patients (BMI<18.5) were excluded. We evaluated the concentration of 37 cytokines and used cytometry by time of flight to characterize im
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet-
Our first 2025 paper was published today in JITC Explores the "obesity paradox" in cancer immunotherapy: 1️⃣ Obese patients have better IO outcomes (despite ⬆️cancer risk) 2️⃣ Obesity → ⬆️T-cell exhaustion →⬆️ ICI benefit https://t.co/0VFM1YpFF3 https://t.co/afX32qFqMw
-
-
Mashup Score: 276Pan-tumor analysis to investigate the obesity paradox in immune checkpoint blockade - 3 month(s) ago
Background Obesity is a risk factor for developing cancer but is also associated with improved outcomes after treatment with immune checkpoint inhibitors (ICIs), a phenomenon called the obesity paradox. To interrogate mechanisms of divergent immune responses in obese and non-obese patients, we examined the relationship among obesity status, clinical responses, and immune profiles from a diverse, pan-tumor cohort of patients treated with ICI-based therapy. Methods From June 2021 to March 2023, we prospectively collected serial peripheral blood samples from patients with advanced or metastatic solid tumors who received ICI as standard of care at Johns Hopkins. Patients were stratified by obesity status at treatment initiation, with obesity defined as body mass index (BMI)≥30 at treatment initiation and BMI≥18.5 and <30 considered non-obese; underweight patients (BMI<18.5) were excluded. We evaluated the concentration of 37 cytokines and used cytometry by time of flight to characterize im
Source: jitc.bmj.comCategories: General Medicine News, Hem/OncsTweet-
Our first 2025 paper was published today in JITC Explores the "obesity paradox" in cancer immunotherapy: 1️⃣ Obese patients have better IO outcomes (despite ⬆️cancer risk) 2️⃣ Obesity → ⬆️T-cell exhaustion →⬆️ ICI benefit https://t.co/0VFM1YpFF3 https://t.co/afX32qFqMw
-
-
Mashup Score: 0Involuted TLS as a harbinger of HCC regression - 6 month(s) ago
Nature Immunology – Tertiary lymphoid structures (TLS) have different stages and cellular compositions in human tumors. New data are showing the effect of neoadjuvant immunotherapy on the fate of…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
8/8 A great editorial from Xin Liu & Dan G. Duda is also worth a read! https://t.co/pSNBrdIAp3 https://t.co/DTeTctbpDu
-
-
Mashup Score: 71Immunotherapy response induces divergent tertiary lymphoid structure morphologies in hepatocellular carcinoma - 6 month(s) ago
Nature Immunology – Here the authors functionally characterize hepatocellular carcinoma associated tertiary lymphoid structures (TLS) in patients treated with neoadjuvant immunotherapy and present…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet-
1/8 Excited to share our latest study in @NatImmunol led by @DanielShuMD on TLS in #HCC patients treated w/ neoadj ICB: ⏩ TLS linked to improved outcomes ⏩ Novel "involuted" TLS found in tumor regression zones 🔗 https://t.co/9ZRX6RDDcY https://t.co/BGz6JICxzm
-
-
Mashup Score: 3Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity - PubMed - 6 month(s) ago
Immune checkpoint blockade (ICB) therapy frequently induces immune-related adverse events. To elucidate the underlying immunobiology, we performed a deep immune analysis of intestinal, colitis, and tumor tissue from ICB-treated patients with parallel studies in preclinical models. Expression of inte …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
3/ ⏫IL-6 associated with ⏫irAEs and⏬tumor response—suggesting IL-6 may “decouple” ICI efficacy from toxicity. Confirms a signal previously demonstrated by @adi_diab (https://t.co/zSU1dB3fx9). Insightful commentary: https://t.co/yvoGpak8lL
-
As U.S. biotech investment stalls (many companies now worth less than cash on hand) and NIH funding dims, China is playing the long game—aiming to do in biotech what it already did in batteries https://t.co/YJmbtnRKt8